CTLA-4Ig blocks the development and progression of citrullinated fibrinogen-induced arthritis in DR4-transgenic mice

Arthritis and Rheumatism

Volumn 62, Issue 10, 2010, Pages 2941-2952

  Yue, David ^a   Brintnell, William ^a   Mannik, Lisa A ^a   Christie, Darah A ^a   Haeryfar, S M Mansour ^a   Madrenas, Joaquín ^b   Chakrabarti, Subrata ^a   Bell, David A ^a   Cairns, Ewa ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; CITRULLINE; FIBRINOGEN; IMMUNOGLOBULIN G1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANKLE EDEMA; ARTHRITIS; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HISTOPATHOLOGY; IMMUNE RESPONSE; JOINT INJURY; LYMPHOCYTE TRANSFER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECIPIENT; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; IMMUNOCONJUGATES; MICE; MICE, TRANSGENIC; T-LYMPHOCYTES;

EID: 77957656301     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.27597     Document Type: Article

References (50)

1. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987;30: 1205-13.
2. Meyer JM, Evans TI, Small RE, Redford TW, Han J, Singh R, et al. HLA-DRB1 genotype influences risk for and severity of rheumatoid arthritis. J Rheumatol 1999;26:1024-34. (Pubitemid 29215064)
3. Hill JA, Southwood S, Sette A, Jevnikar AM, Bell DA, Cairns E. The conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1* 0401 MHC class II molecule. J Immunol 2003;171:538-41. (Pubitemid 36871358)
4. Van Gaalen FA, van Aken J, Huizinga TW, Schreuder GM, Breedveld FC, Zanelli E, et al. Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. Arthritis Rheum 2004;50:2113-21.
5. Klareskog L, Stolt P, Lundberg K, Kallberg H, Bengtsson C, Grunewald J, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA - DR (shared epitope) - restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006;54:38-46.
6. Van der Helm-van Mil AH, Verpoort KN, le Cessie S, Huizinga TW, de Vries RR, Toes RE. The HLA - DRB1 shared epitope alleles differ in the interaction with smoking and predisposition to antibodies to cyclic citrullinated peptide. Arthritis Rheum 2007; 56:425-32.
7. Lee DM, Schur PH. Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Ann Rheum Dis 2003;62:870-4.
8. Goldbach-Mansky R, Lee J, McCoy A, Hoxworth J, Yarboro C, Smolen JS, et al. Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res 2000;2: 236-43.
9. Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, van den Hoogen FH, van 't Hof M, et al. The prognostic value of anti - cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000;43:1831-5.
10. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003;48:2741-9. (Pubitemid 37280601)
11. Berglin E, Padyukov L, Sundin U, Hallmans G, Stenlund H, van Venrooij WJ, et al. A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis. Arthritis Res Ther 2004;6:303-8.
12. Van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL, et al. Autoantibodies to cyclic citrul-linated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 2004;50:709-15.
13. Takizawa Y, Suzuki A, Sawada T, Ohsaka M, Inoue T, Yamada R, et al. Citrullinated fibrinogen detected as a soluble citrullinated autoantigen in rheumatoid arthritis synovial fluids. Ann Rheum Dis 2006;65:1013-20. (Pubitemid 44133262)
14. Masson-Bessiere C, Sebbag M, Girbal-Neuhauser E, Nogueira L, Vincent C, Senshu T, et al. The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the α- and β-chains of fibrin. J Immunol 2001;166:4177-84. (Pubitemid 32224951)
15. Tabushi Y, Nakanishi T, Takeuchi T, Nakajima M, Ueda K, Kotani T, et al. Detection of citrullinated proteins in synovial fluids derived from patients with rheumatoid arthritis by proteomics- based analysis. Ann Clin Biochem 2008;45:413-7.
16. Tilleman K, Van Steendam K, Cantaert T, De Keyser F, Elewaut D, Deforce D. Synovial detection and autoantibody reactivity of processed citrullinated isoforms of vimentin in inflammatory arthritides. Rheumatology (Oxford) 2008;47:597-604. (Pubitemid 351619196)
17. Despres N, Boire G, Menard HA. The rheumatoid arthritis specific Sa autoantigen is present in high concentration in the target tissue [abstract]. Arthritis Rheum 1992;35 Suppl:S72.
18. Kinloch A, Lundberg K, Wait R, Wegner N, Lim NH, Zendman AJ, et al. Synovial fluid is a site of citrullination of autoantigens in inflammatory arthritis. Arthritis Rheum 2008;58:2287-95.
19. Goeb V, Thomas-L'Otellier M, Daveau R, Charlionet R, Fardellone P, Le Loet X, et al. Candidate autoantigens identified by mass spectrometry in early rheumatoid arthritis are chaperones and citrullinated glycolytic enzymes. Arthritis Res Ther 2009;11:R38.
20. Hill JA, Al-Bishri J, Gladman DD, Cairns E, Bell DA. Serum autoantibodies that bind citrullinated fibrinogen are frequently found in patients with rheumatoid arthritis. J Rheumatol 2006;33: 2115-9. (Pubitemid 44749766)
21. Vossenaar ER, Despres N, Lapointe E, van der Heijden A, Lora M, Senshu T, et al. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther 2004;6:142-50.
22. Lundberg K, Kinloch A, Fisher BA, Wegner N, Wait R, Charles P, et al. Antibodies to citrullinated α-enolase peptide 1 are specific for rheumatoid arthritis and cross-react with bacterial enolase. Arthritis Rheum 2008;58:3009-19.
23. Snir O, Widhe M, von Spee C, Lindberg J, Padyukov L, Lundberg K, et al. Multiple antibody reactivities to citrullinated antigens in sera from patients with rheumatoid arthritis: Association with HLA-DRB1 alleles. Ann Rheum Dis 2009;68:736-43.
24. Hill JA, Bell DA, Brintnell W, Yue D, Wehrli B, Jevnikar AM, et al. Arthritis induced by posttranslationally modified (citrullinated) fibrinogen in DR4-IE transgenic mice. J Exp Med 2008;205: 967-79.
25. Panayi GS, Lanchbury JS, Kingsley GH. The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis [editorial]. Arthritis Rheum 1992;35:729-35.
26. Steiner G, Tohidast-Akrad M, Witzmann G, Vesely M, Studnicka- Benke A, Gal A, et al. Cytokine production by synovial T cells in rheumatoid arthritis. Rheumatology (Oxford) 1999;38:202-13. (Pubitemid 29507155)
27. Walunas TL, Bakker CY, Bluestone JA. CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med 1996;183:2541-50.
28. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991;174:561-9.
29. Linsley PS, Wallace PM, Johnson J, Gibson MG, Greene JL, Ledbetter JA, et al. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 1992;257:792-5.
30. Lenschow DJ, Zeng Y, Thistlethwaite JR, Montag A, Brady W, Gibson MG, et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science 1992;257:789-92.
31. Khoury SJ, Akalin E, Chandraker A, Turka LA, Linsley PS, Sayegh MH, et al. CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system. J Immunol 1995;155:4521-4.
32. Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science 1994;265:1225-7.
33. Webb LM, Walmsley MJ, Feldmann M. Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2. Eur J Immunol 1996;26:2320-8. (Pubitemid 26340930)
34. Teft WA, Kirchhof MG, Madrenas J. A molecular perspective of CTLA-4 function. Annu Rev Immunol 2006;24:65-97.
35. Ito K, Bian HJ, Molina M, Han J, Magram J, Saar E, et al. HLA-DR4-IE chimeric class II transgenic, murine class II-deficient mice are susceptible to experimental allergic encephalomyelitis. J Exp Med 1996;183:2635-44.
36. g7 dimer generation. J Autoimmun 1998;11:63-71.
37. Kawane K, Ohtani M, Miwa K, Kizawa T, Kanbara Y, Yoshioka Y, et al. Chronic polyarthritis caused by mammalian DNA that escapes from degradation in macrophages. Nature 2006;443: 998-1002. (Pubitemid 44646177)
38. Genant HK, Peterfy CG, Westhovens R, Becker JC, Aranda R, Vratsanos G, et al. Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial. Ann Rheum Dis 2008;67:1084-9.
39. Knoerzer DB, Karr RW, Schwartz BD, Mengle-Gaw LJ. Collagen-induced arthritis in the BB rat: prevention of disease by treatment with CTLA-4-Ig. J Clin Invest 1995;96:987-93.
40. Kotake S, Udagawa N, Hakoda M, Mogi M, Yano K, Tsuda E, et al. Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum 2001;44: 1003-12.
41. Axmann R, Herman S, Zaiss M, Franz S, Polzer K, Zwerina J, et al. CTLA-4 directly inhibits osteoclast formation. Ann Rheum Dis 2008;67:1603-9.
42. Razmara M, Hilliard B, Ziarani AK, Chen YH, Tykocinski ML. CTLA-4-Ig converts naive CD4+CD25-T cells into CD4+CD25+ regulatory T cells. Int Immunol 2008;20:471-83.
43. Linsen L, Thewissen M, Baeten K, Somers V, Geusens P, Raus J, et al. Peripheral blood but not synovial fluid natural killer T cells are biased towards a Th1-like phenotype in rheumatoid arthritis. Arthritis Res Ther 2005;7:R493-502.
44. Chu EB, Hobbs MV, Wilson CB, Romball CG, Linsley PS, Weigle WO. Intervention of CD4+ cell subset shifts and autoimmunity in the BXSB mouse by murine CTLA4Ig. J Immunol 1996;156: 1262-8.
45. Traggiai E, Puzone R, Lanzavecchia A. Antigen dependent and independent mechanisms that sustain serum antibody levels. Vaccine 2003;21 Suppl 2:S35-7. (Pubitemid 36588647)
46. Rosengren S, Wei N, Kalunian KC, Zvaifler NJ, Kavanaugh A, Boyle DL. Elevated autoantibody content in rheumatoid arthritis synovia with lymphoid aggregates and the effect of rituximab. Arthritis Res Ther 2008;10:R105.
47. Carman JA, Davis PM, Yang WP, Zhu J, Chang H, He A, et al. Abatacept does not induce direct gene expression changes in antigen-presenting cells. J Clin Immunol 2009;29:479-89.
48. Croft M, Bradley LM, Swain SL. Naive versus memory CD4 T cell response to antigen: memory cells are less dependent on accessory cell costimulation and can respond to many antigen-presenting cell types including resting B cells. J Immunol 1994;152:2675-85. (Pubitemid 24097962)
49. Makrygiannakis D, af Klint E, Lundberg IE, Lofberg R, Ulfgren AK, Klareskog L, et al. Citrullination is an inflammation-dependent process. Ann Rheum Dis 2006;65:1219-22.
50. Vossenaar ER, Radstake TR, van der Heijden A, van Mansum MA, Dieteren C, de Rooij DJ, et al. Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages. Ann Rheum Dis 2004;63:373-81.